**Supplementary Table 1. Systemic therapy at each relapse**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **First relapse**  **(n=35)** | **Second relapse**  **(n=24)** | **Third relapse and beyond**  **(n=15)** |
| **BTK inhibitors** | 3 | 5 | 7 |
| Single agent | 3 | 4 | 4 |
| With other agents† | 0 | 1 | 3 |
| **Bortezomib** | 6 | 2 | 3 |
| Single agent | 1 | 0 | 2 |
| With other agents‡ | 5 | 2 | 1 |
| **Lenalidomide** | 1 | 2 | 2 |
| Single agent | 1 | 1 | 1 |
| With Rituximab | 0 | 1 | 1 |
| **Chemotherapy** | 19 | 12 | 13 |
| Rituximab-Bendamustine | 9 | 3 | 1 |
| Other regimen | 10\* | 9# | 12^ |
| **Nil systemic therapy** | 6 | 3 | 3 |
| Supportive care alone/unknown | 3 | 2 | 1 |
| Others ‡‡ | 3 | 1 | 2 |
| *† Ibrutinib + temsirolimus (n=1),*  *Ibrutinib + rituximab (n=2),*  *ibrutinib + venetoclax (n=1)*  *‡ Velcade + rituximab (n=3),*  *Velcade + rituximab + others (n=2),*  *Velcade + rituximab + lenalidomide (n=1),*  *Velcade + rituximab + bendamustine (n=2),*  *‡‡ Surgical resection (n=2)*  *RT alone (n=4)* | *\** *CHOP-like (n=4)*  *Gemcitabine-containing (n=1)*  *Ara-C containing (n=2)*  *Others (n=3)* | *# CHOP-like (n=3)*  *Ara-C containing (n=2)*  *Others (n=4)* | *^ CHOP-like (n=1)*  *Gemcitabine-containing (n=3)*  *Ara-C containing (n=5)*  *Others (n=3)* |